Accuray Enters Exchange Agreements and Secures New Credit

Accuray ( (ARAY) ) just unveiled an update.

On June 5, 2025, Accuray Incorporated entered into exchange agreements with holders of its 3.75% Convertible Senior Notes due 2026, exchanging $82 million in notes for shares and cash, with the transaction expected to close on June 11, 2025. Additionally, Accuray secured a new senior secured credit agreement with TCW Asset Management, providing $150 million in term loans and additional facilities to refinance existing debt and support future operations, enhancing liquidity and operational flexibility.

The most recent analyst rating on (ARAY) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Accuray stock, see the ARAY Stock Forecast page.

Spark’s Take on ARAY Stock

According to Spark, TipRanks’ AI Analyst, ARAY is a Neutral.

Accuray’s overall stock score reflects moderate financial performance and strong earnings call results, tempered by technical indicators and valuation concerns. The company shows potential with revenue growth and improved cash flow, but high leverage and market uncertainties remain significant risks.

To see Spark’s full report on ARAY stock, click here.

More about Accuray

Accuray is a company focused on expanding the potential of radiation therapy to improve patient outcomes. They develop innovative solutions for delivering radiation treatments for complex and common cases, aiming to meet diverse patient needs. Accuray is dedicated to continuous innovation in radiation therapy for oncology and neuro-radiosurgery, partnering with clinicians and administrators to enhance patient care.

Average Trading Volume: 614,386

Technical Sentiment Signal: Sell

Current Market Cap: $163.8M

Find detailed analytics on ARAY stock on TipRanks’ Stock Analysis page.